281 related articles for article (PubMed ID: 36153871)
1. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
Shen LJ; Zhuansun SY; Ni BW; Zhang MY; Lu SS; Hua YN; Xiao D; Huang HH; Han XF; Zhong L; Zhong H; Wang T; Hou J
Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2861-2867. PubMed ID: 36153871
[No Abstract] [Full Text] [Related]
2. [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].
Yan S; Jin S; Wang PF; Yan LZ; Shang JJ; Shi XL; Wu XJ; Zhai YY; Yao WQ; Wang J; Yao Y; Fu CC
Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):819-825. PubMed ID: 37394852
[No Abstract] [Full Text] [Related]
3. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].
Xu JY; Yan WW; Fan HS; Liu JH; Du CX; Deng SH; Sui WW; Xu Y; Qiu LG; An G
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2338-2344. PubMed ID: 35970791
[No Abstract] [Full Text] [Related]
4. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
[TBL] [Abstract][Full Text] [Related]
5. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Pasvolsky O; Ma J; Srour S; Bashir Q; Saini N; Hosing C; Popat UR; Kebriaei P; Delgado R; Ullah MR; Murphy R; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2022 Jun; 28(6):307.e1-307.e8. PubMed ID: 35331973
[TBL] [Abstract][Full Text] [Related]
6. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experience.
Sim S; Quach H; Pham T; Smooker V; Filshie R
Intern Med J; 2024 Jan; 54(1):108-114. PubMed ID: 37357752
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.
Major A; Jakubowiak A; Derman B
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e1000-e1008. PubMed ID: 35922273
[TBL] [Abstract][Full Text] [Related]
10. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
[No Abstract] [Full Text] [Related]
11. [New agents-based induction chemotherapy followed by autologous stem cell transplantation and maintenance treatment strategy for multiple myeloma: a single center retrospective study of 300 cases].
Liu JR; Gu JL; Huang BH; Kuang LF; Chen ML; Zou WY; Zheng D; Wang HH; Xu DR; Li J
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1003-1009. PubMed ID: 36709105
[No Abstract] [Full Text] [Related]
12. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Pasvolsky O; Ghanem S; Milton DR; Masood A; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2023 Dec; 29(12):757-762. PubMed ID: 37673125
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
16. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.
Gaballa MR; Ma J; Rauf M; Bassett R; Pasvolsky O; Tanner MR; Bashir Q; Srour SA; Saini N; Ramdial J; Nieto Y; Murphy R; Rezvani K; Tang G; Lin P; Lee HC; Patel KK; Ullah MR; Kaufman GP; Manasanch EE; Kebriaei P; Thomas SK; Weber DM; Shpall EJ; Champlin RE; Orlowski RZ; Qazilbash MH
Bone Marrow Transplant; 2022 Jul; 57(7):1142-1149. PubMed ID: 35523847
[TBL] [Abstract][Full Text] [Related]
17. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.
Ebraheem M; Kumar SK; Dispenzieri A; Jevremovic D; Buadi FK; Dingli D; Cook J; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Binder M; Lin Y; Go RS; Siddiqui MA; Kyle RA; Rajkumar SV; Gonsalves WI; Gertz MA
Transplant Cell Ther; 2022 Nov; 28(11):760.e1-760.e5. PubMed ID: 35940527
[TBL] [Abstract][Full Text] [Related]
18. [Busulfan, cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma].
Zhang CY; Fu WJ; Xi H; Zhou LL; Jiang H; Du J; Fan JL; Li R; Jin LN; Zeng TM; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):313-6. PubMed ID: 23668203
[TBL] [Abstract][Full Text] [Related]
19. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Bal S; Landau HJ; Shah GL; Scordo M; Dahi P; Lahoud OB; Hassoun H; Hultcrantz M; Korde N; Lendvai N; Lesokhin AM; Mailankody S; Shah UA; Smith E; Devlin SM; Avecilla S; Dogan A; Roshal M; Landgren O; Giralt SA; Chung DJ
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1394-1401. PubMed ID: 32442725
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.
Tanaka K; Toyota S; Akiyama M; Wakimoto N; Nakamura Y; Najima Y; Doki N; Kakihana K; Igarashi A; Kobayashi T; Ohashi K; Kudo D; Shinagawa A; Takano H; Fujio T; Okoshi Y; Hori M; Kumagai T; Saito T; Mukae J; Yamamoto K; Tsutsumi I; Komeno T; Yoshida C; Yamamoto M; Kojima H;
Acta Haematol; 2019; 141(2):111-118. PubMed ID: 30726834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
